Heart Failure, Myocardial Infarction
Conditions
Keywords
Traditional Chinese Medicine
Brief summary
To elucidate the efficacy and safety of weixin decoction in the treatment of heart failure after myocardial infarction.
Detailed description
To elucidate the long-term protective effect of flavored Wenxin Decoction on heart failure after myocardial infarction. To elucidate the effective components in the treatment of heart failure and the mechanism of metabolism regulation.
Interventions
DRUGModified Wenxin Decoction
Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Sponsors
Jun Li
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18-75 years old； * A history of acute myocardial infarction； * Cardiac function Ⅱ - Ⅲ level； * LVEF 50% or less; * Nt-probnp level ≥ 450 pg/ mL； * All men and women can sign the informed consent form.
Exclusion criteria
* Coronary artery bypass grafting was performed within 12 weeks； * Undergo or possibly undergo cardiac resynchronization therapy; * Primary valvular disease, left ventricular outflow tract obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris, or acute myocardial infarction; * Having a serious primary liver, kidney or blood system disease or having a serious mental illness or a systemic disease that is out of control; * Serum creatinine \> 194.5 mol/L or serum potassium \> 5.5mmol /L; * The level of alanine aminotransferase or alkaline phosphatase is 1.5 times of the normal upper limit of \>; * Abnormal blood pressure control, systolic blood pressure exceeding 180mmHg or diastolic blood pressure exceeding 110mmHg; * Pregnancy or lactation; Known or suspected allergy to research drugs; To receive another investigational drug within 30 days of randomization or to be unwilling or unable to provide written consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major cardiovascular events | One months after drug intervention | Rates of cardiac death, acute myocardial infarction, stroke, and heart failure readmission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary indicators | Into the group day 1, week 4, week 8, week 12 | NT-proBNP， six-minute walking experiment and echocardiographic |
Contacts
Primary ContactJun Li, MD
Outcome results
None listed